Mandate

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.

Calliditas Therapeutics is a biopharma company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market in the US focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The total value of the offer amounts to approximately SEK 11,164 million, based on the total number of outstanding shares in Calliditas Therapeutics. Vinge advises Calliditas Therapeutics.

Vinge’s team has mainly consisted of Dain Hård Nevonen, Linnéa Sellström, William Kåge and Benjamin Vafaeian (Capital Markets and Public M&A) and Daniel Wendelsson (FDI).

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026